122 related articles for article (PubMed ID: 16079613)
1. [Development of an individualized therapy for establishing the optimal dosage by the pharmacokinetics profiles of anticancer agents].
Hamada A
Yakugaku Zasshi; 2005 Aug; 125(8):631-7. PubMed ID: 16079613
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of amrubicin and its active metabolite amrubicinol in lung cancer patients.
Matsunaga Y; Hamada A; Okamoto I; Sasaki J; Moriyama E; Kishi H; Matsumoto M; Hira A; Watanabe H; Saito H
Ther Drug Monit; 2006 Feb; 28(1):76-82. PubMed ID: 16418698
[TBL] [Abstract][Full Text] [Related]
3. Phase I and pharmacokinetic study of amrubicin, a synthetic 9-aminoanthracycline, in patients with refractory or relapsed lung cancer.
Okamoto I; Hamada A; Matsunaga Y; Sasaki J; Fujii S; Uramoto H; Yamagata H; Mori I; Kishi H; Semba H; Saito H
Cancer Chemother Pharmacol; 2006 Feb; 57(3):282-8. PubMed ID: 16028099
[TBL] [Abstract][Full Text] [Related]
4. Individual optimal dose of amrubicin to prevent severe neutropenia in Japanese patients with lung cancer.
Makino Y; Makihara-Ando R; Ogawa T; Sato H; Goto Y; Kanda S; Horinouchi H; Fujiwara Y; Ohe Y; Yamamoto N
Cancer Sci; 2019 Nov; 110(11):3573-3583. PubMed ID: 31505087
[TBL] [Abstract][Full Text] [Related]
5. Plasma concentration of amrubicinol in plateau phase in patients treated for 3 days with amrubicin is correlated with hematological toxicities.
Kimura T; Kudoh S; Mitsuoka S; Yoshimura N; Tanaka H; Asai K; Kyoh S; Tochino Y; Umekawa K; Hirata K
Anticancer Drugs; 2009 Jul; 20(6):513-8. PubMed ID: 19352172
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic and pharmacodynamic study on amrubicin and amrubicinol in Japanese patients with lung cancer.
Makino Y; Yamamoto N; Sato H; Ando R; Goto Y; Tanai C; Asahina H; Nokihara H; Sekine I; Kunitoh H; Ohe Y; Sugiyama E; Yokote N; Tamura T; Yamamoto H
Cancer Chemother Pharmacol; 2012 Apr; 69(4):861-9. PubMed ID: 22042514
[TBL] [Abstract][Full Text] [Related]
7. Phase I study to assess the pharmacokinetics and the effect on cardiac repolarization of amrubicin and amrubicinol in patients with advanced solid tumors.
Chen N; Chawla SP; Chiorean EG; Read WL; Gorbaty M; Mita AC; Yung L; Bryan P; McNally R; Renschler MF; Sharma S
Cancer Chemother Pharmacol; 2013 Apr; 71(4):1083-94. PubMed ID: 23400695
[TBL] [Abstract][Full Text] [Related]
8. [Pharmacokinetic study of amrubicin in a case of small lung cancer on hemodialysis].
Ohsawa M; Demizu M; Chihara S; Ueda H; Igarashi T; Tomiyama N; Nakashima Y; Hosoi K; Min K
Gan To Kagaku Ryoho; 2009 Aug; 36(8):1311-4. PubMed ID: 19692770
[TBL] [Abstract][Full Text] [Related]
9. Role of P-glycoprotein in accumulation and cytotoxicity of amrubicin and amrubicinol in MDR1 gene-transfected LLC-PK1 cells and human A549 lung adenocarcinoma cells.
Hira A; Watanabe H; Maeda Y; Yokoo K; Sanematsu E; Fujii J; Sasaki J; Hamada A; Saito H
Biochem Pharmacol; 2008 Feb; 75(4):973-80. PubMed ID: 18054347
[TBL] [Abstract][Full Text] [Related]
10. Tumor-selective distribution of an active metabolite of the 9-aminoanthracycline amrubicin.
Noguchi T; Ichii S; Morisada S; Yamaoka T; Yanagi Y
Jpn J Cancer Res; 1998 Oct; 89(10):1061-6. PubMed ID: 9849586
[TBL] [Abstract][Full Text] [Related]
11. Uptake and intracellular distribution of amrubicin, a novel 9-amino-anthracycline, and its active metabolite amrubicinol in P388 murine leukemia cells.
Yamaoka T; Hanada M; Ichii S; Morisada S; Noguchi T; Yanagi Y
Jpn J Cancer Res; 1999 Jun; 90(6):685-90. PubMed ID: 10429662
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group (WJTOG) study.
Takeda K; Takifuji N; Negoro S; Furuse K; Nakamura S; Takada Y; Hoso T; Hayasaka S; Nakano T; Araki J; Senba H; Iwami F; Yamaji Y; Fukuoka M; Ikegami H
Invest New Drugs; 2007 Aug; 25(4):377-83. PubMed ID: 17351748
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxicity of amrubicin, a novel 9-aminoanthracycline, and its active metabolite amrubicinol on human tumor cells.
Yamaoka T; Hanada M; Ichii S; Morisada S; Noguchi T; Yanagi Y
Jpn J Cancer Res; 1998 Oct; 89(10):1067-73. PubMed ID: 9849587
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous optimization of limited sampling points for pharmacokinetic analysis of amrubicin and amrubicinol in cancer patients.
Makino Y; Watanabe M; Makihara RA; Nokihara H; Yamamoto N; Ohe Y; Sugiyama E; Sato H; Hayashi Y
Asia Pac J Clin Oncol; 2016 Sep; 12(3):259-64. PubMed ID: 26948073
[TBL] [Abstract][Full Text] [Related]
15. [Late phase II clinical study of amrubicin hydrochloride, a novel synthetic anthracycline derivative anticancer agent, for malignant lymphoma].
Akutsu M; Kano Y; Ogawa M; Miura A; Hirano M; Masaoka T; Tatsumi N
Gan To Kagaku Ryoho; 2001 Nov; 28(12):1867-76. PubMed ID: 11729479
[TBL] [Abstract][Full Text] [Related]
16. Phase I and pharmacokinetic study of erlotinib administered in combination with amrubicin in patients with previously treated, advanced non-small cell lung cancer.
Otani S; Hamada A; Sasaki J; Wada M; Yamamoto M; Ryuge S; Takakura A; Fukui T; Yokoba M; Mitsufuji H; Toyooka I; Maki S; Kimura M; Hayashi N; Ishihara M; Kasajima M; Hiyoshi Y; Katono K; Asakuma M; Igawa S; Kubota M; Katagiri M; Saito H; Masuda N
Am J Clin Oncol; 2015 Aug; 38(4):405-10. PubMed ID: 26214085
[TBL] [Abstract][Full Text] [Related]
17. Phase I and pharmacologic study of weekly amrubicin in patients with refractory or relapsed lung cancer: Central Japan Lung Study Group (CJLSG) 0601 trial.
Kitagawa C; Saka H; Kajikawa S; Mori K; Oki M; Suzuki R
Cancer Chemother Pharmacol; 2012 May; 69(5):1379-85. PubMed ID: 22237957
[TBL] [Abstract][Full Text] [Related]
18. Multicenter phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer (Study 1): West Japan Thoracic Oncology Group (WJTOG) trial.
Sawa T; Yana T; Takada M; Sugiura T; Kudoh S; Kamei T; Isobe T; Yamamoto H; Yokota S; Katakami N; Tohda Y; Kawakami A; Nakanishi Y; Ariyoshi Y
Invest New Drugs; 2006 Mar; 24(2):151-8. PubMed ID: 16502350
[TBL] [Abstract][Full Text] [Related]
19. Hematological aspects of a novel 9-aminoanthracycline, amrubicin.
Obara N; Imagawa S; Nakano Y; Yamamoto M; Noguchi T; Nagasawa T
Cancer Sci; 2003 Dec; 94(12):1104-6. PubMed ID: 14662027
[TBL] [Abstract][Full Text] [Related]
20. [Early phase II study of amrubicin (SM-5887) for superficial bladder cancer: a dose-finding study for intravesical chemotherapy].
Tsushima T; Kobashi K; Akebi N; Yamato T; Asahi T; Maki Y; Ohmori H
Gan To Kagaku Ryoho; 2001 Apr; 28(4):483-91. PubMed ID: 11329782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
